GO:0006692 prostanoid metabolic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006692 (prostanoid metabolic process) describes all chemical reactions and pathways involving prostanoids, which are compounds based on or derived from the prostanoate structure.
• Prostanoids are synthesized from arachidonic acid via cyclooxygenase (COX) enzymes and specific terminal synthases, and they act as local hormones in inflammation, vascular tone, and gastrointestinal protection.
• Key genes include PTGS1, PTGS2, and terminal synthases such as PTGES, PTGDS, and TBXAS1, which determine the type of prostanoid produced.
• Dysregulated prostanoid metabolism is implicated in cancer, cardiovascular disease, allergy, and retinal vascular disorders.
• Prostanoid signaling is mediated by G-protein-coupled receptors (e.g., PTGER1-4, PTGFR, PTGIR, TBXA2R), making these pathways druggable targets.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of prostanoid metabolic genes in disease and physiology.
Description
Prostanoid metabolic process (GO:0006692) encompasses the chemical reactions and pathways involving prostanoids, a family of lipid mediators derived from the prostanoate structure. These molecules include prostaglandins (PGs), prostacyclin (PGI2), and thromboxanes (TXs), which are synthesized from arachidonic acid through the coordinated action of cyclooxygenases (COX-1 and COX-2) and terminal synthases. Prostanoids act as autocrine and paracrine signaling molecules that regulate diverse physiological processes such as inflammation, vascular tone, gastrointestinal cytoprotection, and immune responses. Research into prostanoid metabolism is critical because dysregulation of these pathways contributes to numerous human diseases, including cancer, cardiovascular disorders, allergy, and retinal vascular diseases. The druggability of prostanoid pathway enzymes and receptors has made them attractive targets for therapeutic intervention, with nonsteroidal anti-inflammatory drugs (NSAIDs) being classic examples. Understanding the precise roles of individual prostanoid metabolic genes requires sophisticated experimental models, and CRISPR-based gene editing has emerged as a powerful approach to dissect these pathways. This article provides a comprehensive overview of GO:0006692, covering its definition, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods including CRISPR screens and cell models.
prostanoid metabolic process At A Glance
| GO ID | GO:0006692 |
|---|---|
| GO term | prostanoid metabolic process |
| Ontology | biological_process |
| Synonym | prostanoid metabolism |
| Major function | Synthesis and interconversion of prostanoids (prostaglandins, prostacyclin, thromboxanes) from arachidonic acid |
| Key enzymes | Cyclooxygenases (PTGS1, PTGS2), terminal synthases (PTGES, PTGDS, TBXAS1, PTGIS) |
| Substrates | Arachidonic acid, PGH2 |
| Products | PGE2, PGD2, PGF2α, PGI2, TXA2 |
| Associated diseases | Cancer, cardiovascular disease, allergy, retinal vascular disorders |
What Is GO:0006692?
GO:0006692 (prostanoid metabolic process) is defined by the Gene Ontology as the chemical reactions and pathways involving prostanoids, any compound based on or derived from the prostanoate structure. This biological process includes the biosynthesis, conversion, and degradation of prostaglandins, prostacyclin, and thromboxanes, which are synthesized from arachidonic acid via cyclooxygenase-dependent and independent routes. The term captures the enzymatic steps that transform arachidonic acid into bioactive prostanoids and their subsequent metabolism.
Why Is prostanoid metabolic process Important in Cell Biology?
Prostanoid metabolic process is fundamental to human physiology and disease because prostanoids are potent lipid mediators that regulate inflammation, vascular homeostasis, gastrointestinal integrity, and immune responses. Dysregulation of this pathway is implicated in a wide range of pathologies, from cancer and cardiovascular disease to allergy and retinal vascular disorders. Moreover, the pathway is highly druggable, with COX inhibitors (NSAIDs) being among the most widely used medications. Understanding the specific roles of individual prostanoid metabolic genes is essential for developing targeted therapies with fewer side effects.
• Prostanoids are key mediators of inflammation and pain, making this pathway a primary target for anti-inflammatory drugs.
• Prostanoid metabolism regulates vascular tone and permeability, with implications for hypertension and edema.
• Cyclooxygenase-2 (PTGS2) is overexpressed in many cancers and promotes tumor progression.
• Prostanoids contribute to allergic responses and asthma pathogenesis.
• Retinal vascular diseases involve altered prostanoid signaling, offering therapeutic targets.
• Prostanoid receptors are G-protein-coupled receptors that mediate diverse physiological effects.
• Genetic variation in prostanoid pathway genes affects drug response and disease susceptibility.
• CRISPR screens can identify novel regulators of prostanoid metabolism.
• Prostanoid metabolic process is conserved across mammals, facilitating translational research.
• Targeting terminal synthases may provide more selective therapeutic effects than COX inhibition.
What Happens During prostanoid metabolic process?
Release of Arachidonic Acid
In simple terms: The process starts when arachidonic acid is freed from cell membranes.
Prostanoid biosynthesis begins with the release of arachidonic acid from membrane phospholipids, primarily by cytosolic phospholipase A2 (cPLA2) in response to various stimuli. This step is rate-limiting and is tightly regulated by calcium and phosphorylation. Arachidonic acid can also be derived from dietary linoleic acid through elongation and desaturation.
Cyclooxygenase-Mediated Conversion to PGH2
In simple terms: COX enzymes convert arachidonic acid into an unstable intermediate called PGH2.
Arachidonic acid is converted to prostaglandin H2 (PGH2) by cyclooxygenase enzymes, which exist in two isoforms: COX-1 (PTGS1), constitutively expressed in most tissues, and COX-2 (PTGS2), induced by inflammatory stimuli and growth factors. This reaction involves two steps: cyclooxygenation to form PGG2, followed by peroxidation to PGH2. PGH2 is the common precursor for all prostanoids.
Terminal Synthase-Mediated Production of Bioactive Prostanoids
In simple terms: Specific enzymes convert PGH2 into different active prostanoids like PGE2, PGD2, PGF2α, PGI2, and TXA2.
PGH2 is rapidly converted by cell-specific terminal synthases into bioactive prostanoids: PGE2 by prostaglandin E synthases (e.g., PTGES), PGD2 by prostaglandin D synthases (e.g., PTGDS), PGF2α by prostaglandin F synthase, PGI2 by prostacyclin synthase (PTGIS), and TXA2 by thromboxane A synthase (TBXAS1). The expression pattern of these synthases determines the predominant prostanoid produced by a given cell type.
Prostanoid Transport and Receptor Activation
In simple terms: Prostanoids are released from cells and bind to specific receptors on nearby cells to trigger responses.
Prostanoids are released from cells via transporters such as MRP4 and then act locally on G-protein-coupled receptors (GPCRs) to exert their effects. These receptors include PTGER1-4 for PGE2, PTGDR for PGD2, PTGFR for PGF2α, PTGIR for PGI2, and TBXA2R for TXA2. Receptor activation triggers diverse signaling cascades, including cAMP and calcium mobilization, leading to physiological responses.
Degradation and Inactivation of Prostanoids
In simple terms: Prostanoids are quickly broken down to limit their action.
Prostanoids are rapidly metabolized to inactive products to terminate signaling. For example, PGE2 is converted to 15-keto-PGE2 by 15-hydroxyprostaglandin dehydrogenase (15-PGDH, encoded by HPGD), and further reduced by carbonyl reductase. This degradation ensures that prostanoid actions are short-lived and localized.
Key Genes Involved in GO:0006692 prostanoid metabolic process
The following genes encode key enzymes, transporters, and receptors involved in prostanoid metabolic process and its signaling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PTGS1 | Cyclooxygenase-1; constitutive production of prostanoids | Maintenance of gastrointestinal and renal function; target of aspirin |
| PTGS2 | Cyclooxygenase-2; inducible in inflammation and cancer | Major drug target; overexpressed in many tumors |
| PTGES | Prostaglandin E synthase; converts PGH2 to PGE2 | Inflammation, cancer, pain |
| PTGES2 | Prostaglandin E synthase 2; membrane-associated | Alternative PGE2 synthesis pathway |
| PTGDS | Prostaglandin D synthase; produces PGD2 | Allergic responses, sleep regulation |
| PTGIS | Prostacyclin synthase; produces PGI2 | Vascular homeostasis, cardiovascular disease |
| TBXAS1 | Thromboxane A synthase; produces TXA2 | Platelet aggregation, vasoconstriction |
| HPGD | 15-hydroxyprostaglandin dehydrogenase; degrades prostanoids | Termination of prostanoid signaling; tumor suppressor |
| PTGER1 | PGE2 receptor EP1; couples to Gq | Pain, inflammation |
| PTGER2 | PGE2 receptor EP2; couples to Gs | Inflammation, cancer |
| PTGER3 | PGE2 receptor EP3; couples to Gi | Gastroprotection, fever |
| PTGER4 | PGE2 receptor EP4; couples to Gs | Cancer progression, bone remodeling |
| PTGDR | PGD2 receptor DP1; couples to Gs | Allergy, asthma |
| PTGFR | PGF2α receptor FP; couples to Gq | Parturition, ocular pressure |
| PTGIR | PGI2 receptor IP; couples to Gs | Vascular tone, thrombosis |
| TBXA2R | TXA2 receptor TP; couples to Gq | Platelet activation, cardiovascular disease |
| PLA2G4A | Cytosolic phospholipase A2; releases arachidonic acid | Initiation of prostanoid synthesis |
How Is prostanoid metabolic process Regulated?
Prostanoid metabolic process is regulated at multiple levels. The release of arachidonic acid by cPLA2 is controlled by calcium and phosphorylation. COX-2 expression is induced by inflammatory cytokines, growth factors, and tumor promoters, while COX-1 is largely constitutive. Terminal synthase expression is cell-type specific and can be regulated by hormones and inflammatory mediators. Prostanoid degradation by 15-PGDH is also regulated, affecting the duration of prostanoid action. Additionally, receptor desensitization and internalization modulate cellular responses to prostanoids.
prostanoid metabolic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PTGS2 | Colorectal cancer, inflammation | PTGS2 knockout and overexpression in cancer cell lines |
| PTGES | Cancer, pain, inflammation | PTGES knockout mice and cell models |
| TBXAS1 | Cardiovascular disease, thrombosis | TBXAS1 knockout and point mutation models |
| PTGDS | Allergy, asthma | PTGDS knockout and overexpression in mast cells |
| PTGIR | Pulmonary hypertension, thrombosis | PTGIR knockout and knock-in models |
Prostanoid Metabolism in Cancer
Dysregulated prostanoid metabolism, particularly overexpression of PTGS2 and increased PGE2 production, promotes tumor progression by stimulating cell proliferation, angiogenesis, and immune evasion. PGE2 acts through EP2 and EP4 receptors to activate signaling pathways such as PI3K/AKT and cAMP/PKA, contributing to cancer hallmarks. Targeting prostanoid pathway enzymes and receptors is a promising therapeutic strategy in gastrointestinal and other cancers.
Prostanoids in Cardiovascular Disease
Prostanoids play critical roles in vascular homeostasis. Thromboxane A2 (TXA2) is a potent vasoconstrictor and platelet aggregator, while prostacyclin (PGI2) is a vasodilator and inhibitor of platelet aggregation. An imbalance between TXA2 and PGI2 contributes to thrombosis, hypertension, and atherosclerosis. COX-2 selective inhibitors can increase cardiovascular risk by altering this balance.
Prostanoids in Allergy and Inflammation
Prostanoids are key mediators of allergic inflammation. PGD2, produced by mast cells, promotes vasodilation, bronchoconstriction, and eosinophil recruitment through DP1 and CRTH2 receptors. PGE2 can both promote and suppress allergic responses depending on the receptor engaged. Understanding these pathways is essential for developing anti-allergic therapies.
Prostanoids in Retinal Vascular Diseases
Prostanoid signaling is implicated in retinal vascular diseases such as diabetic retinopathy and retinopathy of prematurity. Prostanoids regulate retinal blood flow, vascular permeability, and angiogenesis. Targeting specific prostanoid receptors may offer therapeutic benefits for these conditions.
From prostanoid metabolic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PTGS2 loss affect tumor growth? | PTGS2 knockout in cancer cell lines and xenografts |
| What is the role of PTGES in PGE2 production? | PTGES knockout and overexpression cell models |
| How do point mutations in TBXAS1 alter enzyme activity? | TBXAS1 point mutation knock-in cells |
| Can PTGDS overexpression modulate allergic responses? | PTGDS overexpression in mast cells and mouse models |
| What is the effect of PTGER4 knock-in on cancer progression? | PTGER4 knock-in cell lines and organoids |
| Does PTGIS knockout alter vascular tone? | PTGIS knockout mice and endothelial cells |
How to Study the prostanoid metabolic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality and pathway interactions | Identify novel regulators of prostanoid metabolism |
| RNA-seq | Transcriptional changes | Expression profiling of prostanoid genes in disease |
| Proteomics | Protein abundance and modifications | Quantify COX and synthase levels |
| Lipidomics | Prostanoid levels and profiles | Measure PGE2, PGD2, etc. in biological samples |
| Reporter assays | Receptor activity and signaling | Screen for prostanoid receptor agonists/antagonists |
| Intravital microscopy | Vascular permeability and leukocyte adhesion | Study prostanoid effects in vivo |
| CRISPR activation (CRISPRa) | Gene overexpression | Enhance prostanoid production for study |
| CRISPR interference (CRISPRi) | Gene knockdown | Titrate prostanoid pathway gene expression |
CRISPR-Cas9 Knockout Screens
Genome-wide CRISPR knockout screens can identify genes essential for prostanoid metabolism and signaling. For example, screens targeting the prostanoid pathway can reveal synthetic lethal interactions with PTGS2 inhibitors. These screens use lentiviral sgRNA libraries and next-generation sequencing to quantify sgRNA enrichment or depletion.
Transcriptomic and Proteomic Profiling
RNA-seq and proteomics can measure expression changes in prostanoid pathway genes under different conditions, such as inflammation or cancer. These methods help identify regulatory mechanisms and potential biomarkers.
Lipidomics and Metabolomics
Mass spectrometry-based lipidomics enables quantification of prostanoids and their metabolites in cells and tissues. This approach is critical for validating enzymatic steps and assessing drug effects.
Reporter Assays and Imaging
Fluorescent or luminescent reporters can monitor prostanoid receptor activation and downstream signaling in live cells. Imaging techniques such as intravital microscopy can visualize prostanoid effects on vascular permeability.
How CRISPR Can Be Used to Study GO:0006692 prostanoid metabolic process
Knockout
CRISPR-Cas9 knockout of prostanoid metabolic genes (e.g., PTGS1, PTGS2, PTGES) in cell lines and animal models allows researchers to determine their causal roles in prostanoid production and downstream physiology. Knockout models are essential for validating drug targets and understanding isoform-specific functions.
Point Mutation
Introducing specific point mutations (e.g., in the catalytic domain of PTGS2 or TBXAS1) via CRISPR can mimic human polymorphisms or inactivate enzymatic activity, enabling structure-function studies and personalized medicine approaches.
Knock-in
Knock-in of reporter tags (e.g., GFP) or disease-associated variants into endogenous loci allows real-time monitoring of prostanoid enzyme expression and localization, as well as modeling of genetic diseases.
Overexpression
CRISPR activation (CRISPRa) or cDNA overexpression can elevate prostanoid pathway gene expression to study gain-of-function effects, such as increased PGE2 production in cancer cells.
How EDITGENE Supports prostanoid metabolic process Research
Researchers studying prostanoid metabolic process-related genes often need to determine whether a candidate gene is causally involved in prostanoid synthesis, signaling, or disease progression. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for prostanoid metabolic process research.
Frequently Asked Questions About prostanoid metabolic process
What is prostanoid metabolic process?
Prostanoid metabolic process (GO:0006692) is the set of chemical reactions and pathways involving prostanoids, which are compounds derived from the prostanoate structure, including prostaglandins, prostacyclin, and thromboxanes.
What genes are involved in prostanoid metabolic process?
Key genes include PTGS1, PTGS2, PTGES, PTGDS, PTGIS, TBXAS1, HPGD, and various prostanoid receptors such as PTGER1-4, PTGFR, PTGIR, and TBXA2R.
How are prostanoids synthesized?
Prostanoids are synthesized from arachidonic acid via cyclooxygenase enzymes (COX-1 and COX-2) to form PGH2, which is then converted by terminal synthases into specific prostanoids like PGE2, PGD2, PGF2α, PGI2, and TXA2.
What diseases are associated with prostanoid metabolism?
Dysregulated prostanoid metabolism is linked to cancer, cardiovascular disease, allergy, asthma, and retinal vascular diseases.
What is the role of PTGS2 in prostanoid metabolism?
PTGS2 (COX-2) is an inducible enzyme that produces PGH2 from arachidonic acid, particularly during inflammation and cancer, and is a major drug target.
How can CRISPR be used to study prostanoid metabolism?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect the specific roles of prostanoid pathway genes in cellular and animal models.
What are prostanoid receptors?
Prostanoid receptors are G-protein-coupled receptors that bind specific prostanoids (e.g., PTGER1-4 for PGE2, PTGDR for PGD2) and mediate their physiological effects.
What is the difference between COX-1 and COX-2?
COX-1 (PTGS1) is constitutively expressed and maintains normal physiology, while COX-2 (PTGS2) is induced by inflammation and growth factors.
How are prostanoids degraded?
Prostanoids are rapidly degraded by enzymes such as 15-hydroxyprostaglandin dehydrogenase (HPGD) to terminate their signaling.
Why is prostanoid metabolism important for drug discovery?
The pathway is highly druggable, with NSAIDs targeting COX enzymes; understanding specific prostanoid functions can lead to safer, more selective therapies.
Conclusion
Prostanoid metabolic process (GO:0006692) is a central biological pathway that governs the synthesis, action, and degradation of lipid mediators with profound effects on inflammation, vascular biology, and cancer. The availability of CRISPR-based tools has revolutionized the study of this pathway, enabling precise genetic manipulation to uncover causal roles of individual genes. Continued research into prostanoid metabolism promises to yield new therapeutic strategies for a wide range of diseases.
References
- 1. Wang B et al.. 2021. Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.. Signal Transduct Target Ther 6(1):94 PMID: 33637672
- 2. Inazumi T et al.. 2022. Metabolic Regulation in Adipocytes by Prostanoid Receptors.. Biol Pharm Bull 45(8):992-997 PMID: 35908909
- 3. Mazaleuskaya LL et al.. 2020. Druggable Prostanoid Pathway.. Adv Exp Med Biol 1274:29-54 PMID: 32894506
- 4. Félétou M et al.. 2010. Vasoconstrictor prostanoids.. Pflugers Arch 459(6):941-50 PMID: 20333529
- 5. Stark AK et al.. 2024. Prostanoid signaling in retinal vascular diseases.. Prostaglandins Other Lipid Mediat 174:106864 PMID: 38955261
- 6. Horikami D et al.. 2020. [Prostanoids regulate vascular permeability].. Nihon Yakurigaku Zasshi 155(6):395-400 PMID: 33132257
- 7. Wang D et al.. 2018. Role of prostanoids in gastrointestinal cancer.. J Clin Invest 128(7):2732-2742 PMID: 29733297
- 8. Honda T et al.. 2015. Prostanoids in allergy.. Allergol Int 64(1):11-6 PMID: 25572554
